

Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial hypertension model

Congke Zhao^{a,c,d,1}, Xiangyang Le^{a,c,d,1}, Mengqi Li^{a,c,d}, Yuanbo Hu^{a,c,d}, Xiaohui Li^e, Zhuo Chen^{a,c,d}, Gaoyun Hu^{a,c,d}, Liqing Hu^{b*} and Qianbin Li^{a,c,d,*}

^a *Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China*

^b *Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha 410013, Hunan, China*

^c *Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha 410013, Hunan, China*

^d *Hunan Key Laboratory of Organ Fibrosis, Changsha 410013, Hunan, China*

^e *Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China*

Corresponding author: **Qianbin Li**, qbli@csu.edu.cn; **Liqing Hu**, huliqing@hunnu.edu.cn

¹These authors made equal contributions to this work.

Table of contents:

Figure S1 Compound screening results for the human Hsp110 and ATP binding activity at 100 μ M.....S2

FigureS2 Compound structures and screening results targeting Hsp110/STAT3 signaling at 10 μ M.....S2

Figure S3 Compound screening results targeting the expression of Hsp110 at 10 μ M.....S3


Figure S4 SPR assay for the interaction between KNK437and Hsp110.....S3

Figure S5 The effects of compound 6 on the mRNA levels of Hsp110 in PAECs.....S3

Table S1 Primers used for real-time RT-qPCR.....S4


Original western blots.....S5-S9

Figure S1




Compound screening results for the human Hsp110 and ATP binding activity at 100 μ M.

Figure S2




Compound structures and screening results targeting Hsp110/STAT3 signaling at 10 μ M. Western blot analysis of Hsp110, p-STAT3, STAT3 and c-Myc expression level in HPAECs. Results are expressed as the mean $\pm$ standard error, $n = 3$; $**P < 0.05$ versus the hypoxia group.

Figure S3




Compound screening results targeting the expression of Hsp110 at 10 μM. Results are expressed as the mean ± standard error, $n = 3$; $**P < 0.05$ versus the hypoxia group.

Figure S4



SPR assay for the interaction between KNK437 and Hsp110.

Figure S5



The effects of compound 6 on the mRNA levels of Hsp110 in PAECs. Results are expressed as the mean ± standard error, $n = 3$; $***P < 0.001$ versus the control group, $###P < 0.001$ versus the hypoxia group.

Table S1. Primers used for real-time RT-qPCR

Gene	Forward primer	Reverse primer
Hsp110	5'-ATGAAGTGATGGAATGGATG-3'	5'-TTTGGTTTCGGTTGTGTTAC-3'
GAPDH	5'- AACGGATTGCTCGTATTGGG-3'	5'- CCTGGAAGATGGTGATGGGAT-3'

Original western blots

Fig. 1




Fig. 2




Fig. 3





Fig. 4




Fig. 5




Fig. 7




Figure S2.

